Evidence map›Paper›PMID 38641541›Full record

ArticleEuropean urology oncology2024

Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712.

Zaker Rana, Sophia C Kamran, Amol C Shetty, Philip Sutera, Yang Song, Soha Bazyar, Abhishek A Solanki, Jeffry P Simko, Alan Pollack, David McConkey and 24 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 18 institutions in 2 countries.

Zaker RanaUniversity of Maryland/Greenebaum Cancer Center, Baltimore, MD, USA.
Sophia C KamranMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Amol C ShettyUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Philip SuteraJohns Hopkins University, Baltimore, MD, USA.
Yang SongUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Soha BazyarUniversity of Maryland, Baltimore, MD, USA.
Abhishek A SolankiLoyola University Medical Center, Maywood, IL, USA.
Jeffry P SimkoUCSF Medical Center-Mount Zion, San Francisco, CA, USA.
Alan PollackUniversity of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, FL, USA.
David McConkeyJohns Hopkins University, Baltimore, MD, USA; Sidney Kimmel Cancer Center, Baltimore, MD, USA.
Max KatesJohns Hopkins University, Baltimore, MD, USA; Sidney Kimmel Cancer Center, Baltimore, MD, USA.
M Minhaj SiddiquiUniversity of Maryland, Baltimore, MD, USA.
Jeffrey HikenCoFactor Genomics, San Francisco, CA, USA.
Jon EarlsCoFactor Genomics, San Francisco, CA, USA.
David MessinaCoFactor Genomics, San Francisco, CA, USA.
Kent W MouwDana-Farber/Harvard Cancer Center, Boston, MA, USA.
David MiyamotoMassachusetts General Hospital Cancer Center, Boston, MA, USA.
William U ShipleyMassachusetts General Hospital Cancer Center, Boston, MA, USA.
M Dror MichaelsonMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Anthony ZietmanMassachusetts General Hospital Cancer Center, Boston, MA, USA.
John J CoenDepartment of Radiation Oncology, GenesisCare USA-Warwick, Warwick, RI, USA.
Douglas M DahlMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Ashesh B JaniEmory University Hospital/Winship Cancer Institute, Atlanta, GA, USA.
Luis SouhamiMcGill University Health Centre Research Institute, Montreal, Canada.
Brian K ChangParkview Regional Medical Center, Fort Wayne, IN, USA.
R Jeffrey LeeIntermountain Medical Center, Murray, UT, USA.
Huong PhamVirginia Mason Medical Center, Seattle, WA, USA.
David T MarshallMedical University of South Carolina, Charleston, SC, USA.
Xinglei ShenUniversity of Kansas Cancer Center, Kansas City, KS, USA.
Stephanie L PughNRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA.
Felix Y FengUCSF Medical Center-Mission Bay, San Francisco, CA, USA.
Jason A EfstathiouMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Phuoc T TranUniversity of Maryland/Greenebaum Cancer Center, Baltimore, MD, USA. Electronic address: phuoc.tran@som.umaryland.edu.
Matthew P DeekRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. Electronic address: matthewdeek@gmail.com.
Massachusetts General Hospital · USUniversity of Maryland, Baltimore · USCofactor Genomics (United States) · USJohns Hopkins University · USUniversity of California San Francisco Medical Center · USDana-Farber/Harvard Cancer Center · USEmory University Hospital · USIntermountain Medical Center · USLoyola University Medical Center · USMcGill University Health Centre · CAMedical University of South Carolina · USNRG Oncology · USParkview Health · USRutgers, The State University of New Jersey · USSylvester Comprehensive Cancer Center · USThe University of Kansas Cancer Center · USU-M Rogel Cancer CenterVirginia Mason Medical Center · US

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Elaina Harper · 2014 to 2026
$146.4M
NRG Oncology Biospecimen BankU24CA196067 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Tanner J. Freeman, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$42.6M
Technology CoreU19AI110820 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI WHITE, OWEN R · 2014 to 2023
$36.5M
Resource Sharing CoreU54CA273956 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Phuoc T. Tran · 2022 to 2026
$8.9M
Cardiac microlesion formation during invasive pneumococcal diseaseR01AI114800 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Carlos J Orihuela, Herve S TETTELIN · 2015 to 2026
$5.1M
Tumor-barcoding coupled with high-throughput sequencing of a novel chemoradiation resistant SCLC mouse modelU01CA231776 · NCI · JOHNS HOPKINS UNIVERSITY · PI HANN, CHRISTINE L., MARCHIONNI, LUIGI · 2018 to 2022
$3.9M
Dissecting the role of dynamic epigenome prompting pathways leading to kidney allograft fibrosisR01DK122682 · NIDDK · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI MAS, VALERIA RAQUEL · 2019 to 2023
$3.6M
Integrating bioinformatics into multiscale models for hepatocellular carcinomaU01CA212007 · NCI · JOHNS HOPKINS UNIVERSITY · PI EWALD, ANDREW JOSEF, FERTIG, ELANA · 2018 to 2022
$3.2M
Blood-based monitoring of bladder-sparing trimodality therapy for muscle-invasive bladder cancerR01CA259007 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MIYAMOTO, DAVID T. · 2022 to 2025
$3.0M
Tumor-barcoding coupled with high-throughput sequencing for quantitative radiogenomics of the abscopal response in NSCLCR01CA271540 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Phuoc T. Tran · 2023 to 2026
$2.3M
NCI NIH HHS R01 CA259007NCI NIH HHS R01 CA271540NCI NIH HHS U01 CA212007NCI NIH HHS U01 CA231776NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS U24 CA196067NCI NIH HHS U54 CA273956NIAID NIH HHS R01 AI114800NIAID NIH HHS U19 AI110820NIDDK NIH HHS R01 DK122682
6 · The paper itself

Abstract

Chemoradiation therapy (CRT) is a treatment for muscle-invasive bladder cancer (MIBC). Using a novel transcriptomic profiling panel, we validated prognostic immune biomarkers to CRT using 70 pretreatment tumor samples from prospective trials of MIBC (NRG/RTOG 0524 and 0712). Disease-free survival (DFS) and overall survival (OS) were estimated via the Kaplan-Meier method and stratified by genes correlated with immune cell activation. Cox proportional-hazards models were used to assess group differences. Clustering of gene expression profiles revealed that the cluster with high immune cell content was associated with longer DFS (hazard ratio [HR] 0.53, 95% confidence interval [CI] 0.26-1.10; p = 0.071) and OS (HR 0.48, 95% CI 0.24-0.97; p = 0.040) than the cluster with low immune cell content. Higher expression of T-cell infiltration genes (CD8A and ICOS) was associated with longer DFS (HR 0.40, 95% CI 0.21-0.75; p = 0.005) and OS (HR 0.49, 95% CI 0.25-0.94; p = 0.033). Higher IDO1 expression (IFNγ signature) was also associated with longer DFS (HR 0.44, 95% CI 0.24-0.88; p = 0.021) and OS (HR 0.49, 95% CI 0.24-0.99; p = 0.048). These findings should be validated in prospective CRT trials that include biomarkers, particularly for trials incorporating immunotherapy for MIBC. PATIENT SUMMARY: We analyzed patient samples from two clinical trials (NRG/RTOG 0524 and 0712) of chemoradiation for muscle-invasive bladder cancer using a novel method to assess immune cells in the tumor microenvironment. Higher expression of genes associated with immune activation and high overall immune-cell content were associated with better disease-free survival and overall survival for patients treated with chemoradiation.

Indexed as

ChemoradiotherapyNeoplasm InvasivenessUrinary Bladder NeoplasmsAgedDisease-Free SurvivalFemaleHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedPrognosisBladder cancerChemoradiationImmune cell infiltration

Identifiers

PMID38641541
PMCPMC11427165
OpenAlexW4394936185

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.